Hormonal
Initiation of GLP-1 receptor agonists is associated with a small but statistically significant increased risk of acute pancreatitis, particularly during the first 6 months of treatment.
Be aware that GLP-1 RAs carry a small increased risk of acute pancreatitis, especially in the first 6 months. If you have a history of pancreatitis, discuss this carefully with your doctor. Report severe, persistent abdominal pain to your provider immediately, as it could be a sign of pancreatitis.
GLP-1 RA Users showed a higher risk of acute pancreatitis (HR 1.058, 95% CI 1.015–1.103)... The excess risk of acute pancreatitis was more pronounced during the early phase of follow-up (first 6 months).
Why this rating
Large observational study with PSM, but causality is debated and may be influenced by confounding factors.
Source
Risk of all–cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network
Enrico Tartaglia et al. · Cardiovascular Diabetology · 2025
DOI 10.1186/s12933-025-02986-0
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →